We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cyprotex Launch Updated Drug-Drug Interaction Regulatory Guidance
News

Cyprotex Launch Updated Drug-Drug Interaction Regulatory Guidance

Cyprotex Launch Updated Drug-Drug Interaction Regulatory Guidance
News

Cyprotex Launch Updated Drug-Drug Interaction Regulatory Guidance

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cyprotex Launch Updated Drug-Drug Interaction Regulatory Guidance"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cyprotex PLC have today launched an update of their popular Drug-Drug Interaction Regulatory Guidance booklet.

Important new regulatory guidelines for drug-drug interaction (DDI) studies have been released this year. Initially, draft FDA guidance for drug interactions studies were released for comment in February. In June, the European Medicines Agency (EMA) adopted a new guideline on the investigation of drug interactions and this is due to come into effect as of January 2013.

By popular request from our customers, Cyprotex have constructed an easy-to-follow pocket-sized handbook entitled ‘DDI Regulatory Guidance – An easy to follow guide’ which summarises key information from the latest drug interaction guidance documents. It offers a side-by-side comparison of the recommendations from both the FDA and EMA regulatory authorities. The handbook assists in the design and planning of in vitro DDI studies and provides concise information on how the data are used to guide clinical DDI studies.

Commenting on the launch of the handbook, Dr. Anthony Baxter, Chief Executive Officer of Cyprotex, said: “Our DDI handbook provides a valuable resource for scientists who can now access the key information from the regulatory authorities in an easy-to-read format. The handbook also acts as an educational tool for new scientists in the field who are unfamiliar with these guidelines. We have had an overwhelming response to the revised handbook, with over 500 potential customers already pre-ordering the updated version, which will be distributed later this week.”

Advertisement